We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pfizer and BioNTech, current frontrunners in the race for an approved COVID-19 vaccine, have finalized an agreement with the European Commission to supply 300 million doses of their vaccine starting by year’s end — but the vaccine’s distribution is expected to face serious challenges worldwide because it must be stored at super-cold temperatures. Read More
Efficacy questions are swirling about the 700-mg dose of Eli Lilly’s COVID-19 antibody treatment bamlanivimab that just this week received Emergency Use Authorization (EUA) from the FDA. Read More
ViiV Healthcare released interim results from a late-stage clinical trial that showed its long-acting investigational HIV treatment was 89 percent more effective in preventing infection among women than Truvada, Gilead Sciences’ daily oral pill. Read More